WO1999040947A3 - Angiogenesis targeting molecules - Google Patents

Angiogenesis targeting molecules Download PDF

Info

Publication number
WO1999040947A3
WO1999040947A3 PCT/CA1999/000101 CA9900101W WO9940947A3 WO 1999040947 A3 WO1999040947 A3 WO 1999040947A3 CA 9900101 W CA9900101 W CA 9900101W WO 9940947 A3 WO9940947 A3 WO 9940947A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiogenesis
compounds
targeting molecules
angiogenesis targeting
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1999/000101
Other languages
French (fr)
Other versions
WO1999040947A2 (en
Inventor
Theresa Fauconnier
Alfred Pollak
John Thornback
Dennis Eshima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resolution Pharmaceuticals Inc
Original Assignee
Resolution Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resolution Pharmaceuticals Inc filed Critical Resolution Pharmaceuticals Inc
Priority to EP99903566A priority Critical patent/EP1056773A2/en
Priority to AU24066/99A priority patent/AU757554B2/en
Priority to CA002320339A priority patent/CA2320339A1/en
Publication of WO1999040947A2 publication Critical patent/WO1999040947A2/en
Publication of WO1999040947A3 publication Critical patent/WO1999040947A3/en
Anticipated expiration legal-status Critical
Priority to US10/420,205 priority patent/US20030194373A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compounds that are effective for targeting sites of angiogenesis for diagnostic and therapeutic purposes. The compounds are of the Formula (I): A-(B)n-C, wherein A is a chelator moiety capable of complexing a radionuclide metal or a moiety capable of binding to a halogen; B is a spacer group; C is an angiogenesis targeting molecule; and n is selected from the integers 0 and 1. The invention also relates to a method of imaging sites of angiogenesis and treating patients through the administration of the compounds of the present invention.
PCT/CA1999/000101 1998-02-11 1999-02-11 Angiogenesis targeting molecules Ceased WO1999040947A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99903566A EP1056773A2 (en) 1998-02-11 1999-02-11 Angiogenesis targeting molecules
AU24066/99A AU757554B2 (en) 1998-02-11 1999-02-11 Angiogenesis targeting molecules
CA002320339A CA2320339A1 (en) 1998-02-11 1999-02-11 Angiogenesis targeting molecules
US10/420,205 US20030194373A1 (en) 1998-02-11 2003-04-22 Angiogenesis targeting molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7442098P 1998-02-11 1998-02-11
US60/074,420 1998-02-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US63617900A Continuation 1998-02-11 2000-08-10

Publications (2)

Publication Number Publication Date
WO1999040947A2 WO1999040947A2 (en) 1999-08-19
WO1999040947A3 true WO1999040947A3 (en) 2000-03-23

Family

ID=22119472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000101 Ceased WO1999040947A2 (en) 1998-02-11 1999-02-11 Angiogenesis targeting molecules

Country Status (5)

Country Link
US (1) US20030194373A1 (en)
EP (1) EP1056773A2 (en)
AU (1) AU757554B2 (en)
CA (1) CA2320339A1 (en)
WO (1) WO1999040947A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) * 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
ATE295369T1 (en) * 1998-03-31 2005-05-15 Bristol Myers Squibb Pharma Co PHARMACEUTICALS FOR IMAGING ANGIOGENIC DISEASES
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
DE19845798A1 (en) * 1998-09-29 2000-04-13 Schering Ag Use of neoangiogenesis markers for diagnosis and therapy of tumors, agents containing them, and methods for their production
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349501A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Quinolone vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
CA2362860A1 (en) 1999-02-17 2000-08-24 Bracco International B.V. Immobilized labeling compounds and methods
HK1043314A1 (en) * 1999-06-17 2002-09-13 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting tumor vasculature
US7045133B2 (en) 2000-01-18 2006-05-16 Ludwig Institute For Cancer Research VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US7109167B2 (en) 2000-06-02 2006-09-19 Bracco International B.V. Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
AU7002501A (en) * 2000-06-21 2002-01-02 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
US6506365B1 (en) * 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
FR2814744B1 (en) 2000-10-04 2002-11-29 Commissariat Energie Atomique CYCLOPEPTIDES, THEIR PREPARATION PROCESS AND THEIR USE AS ANGIOGENESIS INHIBITOR OR ACTIVATOR
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20040152769A1 (en) * 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
NO20026285D0 (en) * 2002-12-30 2002-12-30 Amersham Health As New peptides
NO20026286D0 (en) * 2002-12-30 2002-12-30 Amersham Health As New peptides
WO2004069281A1 (en) * 2003-01-30 2004-08-19 The General Hospital Corporation Bifunctional molecules comprising at least one integrin-binding and their use in imaging and therapy of angiogenesis and related disorders
EP2284180B1 (en) 2003-03-03 2015-09-09 Dyax Corp. Uses of peptides that specifically bind HGF receptor (cMET)
FR2856689A1 (en) * 2003-06-25 2004-12-31 Guerbet Sa SPECIFIC COMPOUNDS WITH HIGH RELAXIVITY
CA2625196C (en) 2005-10-07 2016-04-05 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8628750B2 (en) * 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment
FR2942227B1 (en) 2009-02-13 2011-04-15 Guerbet Sa USE OF BUFFERS FOR RADIONUCLEID COMPLEXATION
WO2010143708A1 (en) * 2009-06-12 2010-12-16 富士フイルム株式会社 Targeting agent for neovascularization
JPWO2011083845A1 (en) * 2010-01-08 2013-05-16 富士フイルム株式会社 Targeting agent for tumor site
FR2968999B1 (en) 2010-12-20 2013-01-04 Guerbet Sa CHELATE NANOEMULSION FOR MRI
FR2980364B1 (en) 2011-09-26 2018-08-31 Guerbet NANOEMULSIONS AND THEIR USE AS CONTRAST AGENTS
KR101967345B1 (en) 2012-10-18 2019-04-09 삼성전자주식회사 Peptides for inhibition of binding between angiopoietin-2 and integrin and uses thereof
FR3001154B1 (en) 2013-01-23 2015-06-26 Guerbet Sa MAGNETO-EMULSION VECTORIZED
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359347A2 (en) * 1988-08-15 1990-03-21 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
WO1994011499A1 (en) * 1992-11-13 1994-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Flk-1 is a receptor for vascular endothelial growth factor
WO1995017419A1 (en) * 1993-12-22 1995-06-29 Resolution Pharmaceuticals Inc. Metal chelators
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5620675A (en) * 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
AU7261994A (en) * 1993-07-19 1995-02-20 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n3s configuration
ATE175976T1 (en) * 1993-10-22 1999-02-15 Nihon Mediphysics Co Ltd PEPTIDES WITH AFFINITY FOR INFLAMMATION AND THEIR RADIOM-LABELED, DIAGNOSTIC COMPOSITIONS
US5650490A (en) * 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359347A2 (en) * 1988-08-15 1990-03-21 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
WO1994011499A1 (en) * 1992-11-13 1994-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Flk-1 is a receptor for vascular endothelial growth factor
WO1995017419A1 (en) * 1993-12-22 1995-06-29 Resolution Pharmaceuticals Inc. Metal chelators
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
TAKAGI, H. ET AL.: "Identification and characterization of vascular endothelial growth factor receptor ...", DIABETES, vol. 45, August 1996 (1996-08-01), pages 1016 - 1023, XP002115744 *
TAUNTON, J.: "How to starve a tumor", CHEMISTRY & BIOLOGY, vol. 4, July 1997 (1997-07-01), pages 493 - 496, XP002115745 *
YANAI, S. ET AL.: "Antitumor activity of a medium chain triglyceride solution of the angiogenesis inhibitor TNP-470 ...", J. PHARM. EXP. THER., vol. 271, no. 8, 1994, pages 1267 - 1273, XP002115746 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US9056138B2 (en) 2002-03-01 2015-06-16 Bracco Suisse Sa Multivalent constructs for therapeutic and diagnostic applications
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9381258B2 (en) 2002-03-01 2016-07-05 Bracco Suisse S.A. Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Also Published As

Publication number Publication date
EP1056773A2 (en) 2000-12-06
WO1999040947A2 (en) 1999-08-19
CA2320339A1 (en) 1999-08-19
AU2406699A (en) 1999-08-30
AU757554B2 (en) 2003-02-27
US20030194373A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
DE69514813D1 (en) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
CA2260016A1 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
ES2165969T3 (en) AROMATIC CONDENSED NITROGEN COMPOUNDS 5.5 ARIL-SUBSTITUTED AS ANTI-INFLAMMATORY AGENTS.
CA2283399A1 (en) Pyridazinones as inhibitors of cyclooxygenase-2
BG104727A (en) Pharmaceutical composition of topiramate
DE69825603D1 (en) 2,3,5-TRISUBSTITUTED PYRIDINE AS INHIBITORS OF CYCLOOXYGENASE-2
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
MX9701538A (en) Salts of an anti-migraine indole derivative.
IL154501A0 (en) Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
GB9002922D0 (en) 17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
CA2015475A1 (en) Treating agent for osteoarthritis
EP0699670A3 (en) Arylester compound, process for its preparation and epoxyresin compositions using it, and copper-coated laminate using this composition
EP1813607A3 (en) Tetraaza- or N2S2- complexants, and their use in radiodiagnostics or radiotherapy
WO2001097860A3 (en) Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
AP2002002387A0 (en) Method of inhibiting amyloid aggregation and imaging amyloid deposits.
UA27108A1 (en) Anthracycline glycosides and their pharmaceutically acceptable acid-additive salts, method of their synthesis, diiodointermediate compound and method of its synthesis
CA2211320A1 (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
GR3031114T3 (en) Use of a pregnane derivatives for the treatment of tumours.
CZ63295A3 (en) 1 alpha-fluoro-25-hydroxy-16-en-23-in-cholecalciferol as such and for the use as a therapeutic active compound, its use for the preparation of a pharmaceutical preparation, process of its preparation and a pharmaceutical preparation based thereon
WO2002028880A8 (en) Compounds useful for treating hypertriglyceridemia
IL152941A0 (en) Fused heterocyclic compounds and kits and pharmaceutical compositions containing the same
CA2301590A1 (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
CA2252401A1 (en) Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
AU3282300A (en) Molecules for the treatment and diagnosis of tumors
CA2180624A1 (en) Diphenyl-1,2,3-thiadiazoles as anti-inflammatory agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2320339

Country of ref document: CA

Ref country code: CA

Ref document number: 2320339

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09636179

Country of ref document: US

Ref document number: 24066/99

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999903566

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999903566

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 24066/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999903566

Country of ref document: EP